While the genetic reasons behind imatinib acquired resistance in gastrointestinal stromal tumors (GIST) are well known, the development of new agents to overcome this resistance has been limited. This is due to a lack of preclinical models which fully recapitulate the complex interplay of KIT primary and secondary mutations seen in the clinical population. CrownBio provides the world’s most comprehensive panel of GIST patient-derived xenograft (PDX) models, ideal for the preclinical evaluation of novel therapies to circumvent imatinib resistance. More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.